ClinicalTrials.gg
Not yet recruitingNCT07777354Updated Aug 20, 2026

Comparative Study Between Leg Massage and Vibration on Cramps and Comfort for Patients Undergoing Hemodialysis

An interventional study of massage and vibration in Hemodialysis and Renal Failure , Chronic, sponsored by University of Baghdad. Not yet recruiting. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by University of Baghdad · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
All
01

Study summary

This planned randomized controlled trial will enroll 164 patients undergoing hemodialysis to compare the effectiveness of leg massage versus vibration therapy on muscle cramps and patient comfort. Participants will be randomly assigned to one of three groups: a massage group receiving 20-minute lower extremity massage sessions, a vibration group receiving 10-minute vibration therapy, or a control group receiving standard care only. All interventions will be administered three times per week for two weeks (six sessions). The study will evaluate cramp frequency, cramp severity using a Visual Analog Scale, sleep quality through the Pittsburgh Sleep Quality Index, and patient comfort scores. Both interventions are expected to significantly reduce cramp frequency and severity compared to standard care, with massage anticipated to show superior benefits for sleep quality and home-based cramp reduction, while vibration is expected to provide better immediate comfort during dialysis sessions. No serious adverse events are predicted. The findings will help healthcare providers offer personalized, evidence-based non-pharmacological options to improve quality of life for hemodialysis patients.

Read the detailed description

Muscle cramps are one of the most common and distressing complications experienced by patients undergoing hemodialysis, affecting approximately 33% to 86% of this population. These involuntary, painful muscle contractions, predominantly occurring in the lower extremities, often lead to premature termination of dialysis sessions, sleep disturbances, and significant deterioration in quality of life. While pharmacological interventions such as hypertonic saline, glucose, and carnitine supplements are currently used, their effectiveness remains inconsistent and they may carry adverse effects. Consequently, there is a growing interest in non-pharmacological approaches that are safe, cost-effective, and easily integrated into routine dialysis care. Both leg massage and vibration therapy have shown individual promise in managing muscle cramps and improving patient comfort, yet no large-scale randomized controlled trial has directly compared their relative effectiveness. This study will address this critical knowledge gap by providing head-to-head comparative evidence to guide clinical decision-making.

This study will be designed as a prospective, parallel-group, randomized controlled trial conducted across three outpatient hemodialysis centers. A total of 164 adult patients undergoing maintenance hemodialysis for at least three months who experience lower extremity muscle cramps will be enrolled. After providing informed consent, participants will be stratified based on dialysis session frequency, baseline cramp frequency, age, and gender to ensure homogeneity across groups. Using a computer-generated random sequence, patients will be allocated in a 1:1:1 ratio to one of three groups: the massage group (n=61), the vibration group (n=57), or the control group (n=46). Due to the nature of the interventions, blinding of participants and intervention providers will not be feasible; however, outcome assessors and data analysts will remain blinded to group allocation to minimize detection bias.

Participants in the massage group will receive a standardized 20-minute lower extremity massage during each hemodialysis session, administered three times per week for a total of two weeks (six sessions). The massage protocol will include effleurage (gentle stroking), petrissage (kneading), friction (deep circular movements), and tapotement (rhythmic tapping) applied by trained registered nurses with certification in therapeutic massage. The vibration group will receive 10 minutes of mechanical vibration therapy using a portable device delivering vibration at a frequency of 30-50 Hz with an amplitude of 2-4 mm, applied to the posterior calf, anterior tibial, and quadriceps muscles. The control group will receive standard dialysis care without any additional interventions. The primary outcomes will be cramp frequency (recorded via daily patient diaries during dialysis and at home) and cramp severity measured using a 10-cm Visual Analog Scale (VAS). Secondary outcomes will include sleep quality assessed by the Pittsburgh Sleep Quality Index (PSQI), patient comfort scores during dialysis sessions, and documentation of any adverse events.

It is hypothesized that both massage and vibration interventions will demonstrate significant superiority over standard care in reducing cramp frequency and severity, with each intervention showing distinct advantages in specific outcome domains. Specifically, the massage group is expected to exhibit greater improvement in sleep quality and more substantial reduction in home-based cramping episodes compared to both the vibration and control groups. Conversely, the vibration group is anticipated to achieve higher immediate comfort scores during dialysis sessions, reflecting the shorter intervention duration and potentially greater patient tolerability. Both interventions are predicted to be safe, with no serious adverse events expected. The findings from this trial will provide robust evidence to guide personalized, patient-centered care, enabling healthcare providers to recommend either massage or vibration based on individual patient priorities, clinical presentation, and available resources. Ultimately, integrating these evidence-based non-pharmacological interventions into routine hemodialysis protocols has the potential to substantially improve treatment adherence, patient satisfaction, and overall quality of life for the growing population of patients receiving maintenance hemodialysis.

02

Conditions studied

  • Hemodialysis
  • Renal Failure , Chronic

Keywords

  • Leg massage
  • Vibration
  • Cramps
  • Comfort
  • Hemodialysis
03

In context

Renal Insufficiency, Chronic

3,090 studies on the registry are indexed under Renal Insufficiency, Chronic; 698 are open to participants now.

This study's planned enrollment of 160 is above the median of 73 across 2,157 interventional studies indexed under Renal Insufficiency, Chronic.

Browse Renal Insufficiency, Chronic studies →

Lead sponsor

University of Baghdad is the lead sponsor of 170 studies on the registry; 69 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients on maintenance HD for ≥3 months who experienced lower extremity muscle cramps.

Exclusion criteria

Exclusion Criteria:

  • Exclusion criteria included acute illness, lower extremity wounds/infections, deep vein thrombosis, severe neuropathy, and cognitive impairment. All participants provided written .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • No intervention
    control

    no intervention

  • Experimental
    study

    interventional

    Other: massage · Other: vibration

Interventions

  • Othermassage

    Received a standardized 20-minute lower extremity massage (effleurage, petrissage, friction, tapotement) during each HD session, 3x/week for 2 weeks (6 sessions), administered by trained nurses (19).

  • Othervibration

    Received 10 minutes of mechanical vibration (30-50 Hz, 2-4 mm amplitude) applied to the calf, tibialis anterior, and quadriceps muscles via a portable device during each HD session (20).

06

What researchers measure

Primary outcomes

  1. primary

    • Primary: Cramp frequency (episodes/week during HD and at home via daily diary) and cramp severity (10-cm Visual Analog Scale \[VAS\]) (21).

    Time frame: 2 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.

Of 576 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 3 months is below that.

Counting every sponsor, half of 616 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2026
First posted
Aug 20, 2026
StartEst.
Sep 10, 2026
Primary completionEst.
Dec 10, 2026
CompletionEst.
Dec 12, 2026
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07777354
Responsible party
Maitham abed Shawwat (Al-Muthann health directors, University of Baghdad) — Principal investigator
First posted
Aug 20, 2026
Start date
Sep 10, 2026 (estimated)
Primary completion
Dec 10, 2026 (estimated)
Completion
Dec 12, 2026 (estimated)
Last update
Aug 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion